渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BIIB 渤健公司

已收盘 12-04 16:00:00 EST

181.98

+1.23

+0.68%

盘后182.36

+0.38+0.21%

19:52 EST

最高182.69	最低179.27	成交量124.63万
今开181.86	昨收180.75	日振幅1.89%
总市值266.97亿	流通市值266.10亿	总股本1.47亿
成交额2.26亿	换手率0.85%	流通股本1.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BIIB","market":"US","secType":"STK","nameCN":"渤健公司","latestPrice":181.98,"timestamp":1764882000000,"preClose":180.75,"halted":0,"volume":1246342,"hourTrading":{"tag":"盘后","latestPrice":182.36,"preClose":181.98,"latestTime":"19:52 EST","volume":62355,"amount":11348270.63,"timestamp":1764895963853},"delay":0,"floatShares":146226846,"shares":146702272,"eps":10.974839,"marketStatus":"已收盘","change":1.23,"latestTime":"12-04 16:00:00 EST","open":181.86,"high":182.69,"low":179.27,"amount":226377646.6083,"amplitude":0.018921,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":10.974839,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1764925200000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":685080000000,"exchange":"NASDAQ","adjPreClose":180.75,"preHourTrading":{"tag":"盘前","latestPrice":181,"preClose":180.75,"latestTime":"09:29 EST","volume":604,"amount":109815.51708,"timestamp":1764858599999},"postHourTrading":{"tag":"盘后","latestPrice":182.36,"preClose":181.98,"latestTime":"19:52 EST","volume":62355,"amount":11348270.63,"timestamp":1764895963853},"volumeRatio":0.808449,"impliedVol":0.3217,"impliedVolPercentile":0.068},"requestUrl":"/m/hq/s/BIIB","defaultTab":"news","newsList":[{"id":"1166943636","title":"Eisai 在2025年阿尔茨海默病临床试验会议上展示 Leqembi®（Lecanemab-Irmb）在早期阿尔茨海默病持续和扩展益处的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1166943636","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166943636?lang=zh_cn&edition=full","pubTime":"2025-12-04 07:11","pubTimestamp":1764803473,"startTime":"0","endTime":"0","summary":"Eisai 在2025年阿尔茨海默病临床试验会议上展示 Leqembi®（Lecanemab-Irmb）在早期阿尔茨海默病持续和扩展益处的新数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4139","BK4533","BIIB","BK4585","IE00B894F039.SGD","IE00B19Z9P08.USD","BK4588","IE00B19Z9Z06.USD","LU0234570918.USD"],"gpt_icon":0},{"id":"1183487643","title":"2025年阿尔茨海默病临床试验会议上公布的新数据确认Leqembi® (Lecanemab-Irmb)对脑脊液中神经毒性aβ原纤维的药理作用","url":"https://stock-news.laohu8.com/highlight/detail?id=1183487643","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183487643?lang=zh_cn&edition=full","pubTime":"2025-12-03 05:40","pubTimestamp":1764711612,"startTime":"0","endTime":"0","summary":"2025年阿尔茨海默病临床试验会议上公布的新数据确认Leqembi® (Lecanemab-Irmb)对脑脊液中神经毒性aβ原纤维的药理作用","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BIIB","LU0234570918.USD","LU0889565916.HKD","LU0320765992.SGD","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","BK4585","BK4533","IE00B894F039.SGD","BK4139","LU0109394709.USD","BK4588"],"gpt_icon":0},{"id":"1180289642","title":"Eisai完成对美国FDA的Leqembi® Iqlik™（Lecanemab-Irmb）补充生物制剂许可申请的滚动提交，作为早期阿尔茨海默病的皮下注射启动剂量，已获得快速通道状态","url":"https://stock-news.laohu8.com/highlight/detail?id=1180289642","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180289642?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:30","pubTimestamp":1764073823,"startTime":"0","endTime":"0","summary":"Eisai完成了对美国FDA的Leqembi® Iqlik™（Lecanemab-Irmb）补充生物制剂许可申请的滚动提交，该申请涉及作为早期阿尔茨海默病治疗的皮下注射启动剂量，并已获得快速通道资格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9P08.USD","LU0234570918.USD","BK4533","LU0109394709.USD","BK4139","BK4588","IE00B894F039.SGD","BK4532","IE00B19Z9Z06.USD","LU0889565916.HKD","BK4585","LU0320765992.SGD","BIIB"],"gpt_icon":0},{"id":"1137409579","title":"渤健公司与Dayra Therapeutics宣布研究合作，开发用于多种免疫疾病的口服大环肽","url":"https://stock-news.laohu8.com/highlight/detail?id=1137409579","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137409579?lang=zh_cn&edition=full","pubTime":"2025-11-24 20:31","pubTimestamp":1763987497,"startTime":"0","endTime":"0","summary":"渤健公司与Dayra Therapeutics宣布建立研究合作伙伴关系，旨在发现并开发用于治疗多种免疫疾病的口服大环肽。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","LU0109394709.USD","BK4533","BK4532","LU0234570918.USD","BK4139","BK4585","LU0889565916.HKD","BIIB","BK4588","IE00B19Z9P08.USD","LU0320765992.SGD","IE00B894F039.SGD"],"gpt_icon":0},{"id":"1167349174","title":"诺和诺德新疗法受挫，竞争对手渤健盘前拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=1167349174","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167349174?lang=zh_cn&edition=full","pubTime":"2025-11-24 19:51","pubTimestamp":1763985109,"startTime":"0","endTime":"0","summary":"新疗法未显示出阿尔茨海默病减缓效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c4dd3317d59b6ed3d7569f1d532c0719","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB"],"gpt_icon":0},{"id":"1116946595","title":"努西瑞辛高剂量方案获得CHMP积极意见，用于治疗脊髓性肌萎缩症","url":"https://stock-news.laohu8.com/highlight/detail?id=1116946595","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116946595?lang=zh_cn&edition=full","pubTime":"2025-11-17 19:01","pubTimestamp":1763377303,"startTime":"0","endTime":"0","summary":"努西瑞辛高剂量方案获得CHMP积极意见，用于治疗脊髓性肌萎缩症","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","BK4532","BK4533","IE00B894F039.SGD","BIIB","BK4588","BK4139","LU0889565916.HKD","LU0320765992.SGD","LU0234570918.USD","LU0109394709.USD","BK4585","IE00B19Z9P08.USD"],"gpt_icon":0},{"id":"1144209379","title":"一周美股牛榜 | 美国雅保周涨18%，获大行高看至107美元；礼来升近11%，本周创新高；思科周内涨10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144209379","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144209379?lang=zh_cn&edition=full","pubTime":"2025-11-17 10:48","pubTimestamp":1763347698,"startTime":"0","endTime":"0","summary":"瑞穗证券将其目标价从92美元上调至110美元，瑞银将其目标价从85美元上调至107美元。礼来升10%，股票本周创历史新高礼来公司的股票本周达到历史新高，达到每股1025美元，此前几笔重大交易促使美国食品和药物管理局对其备受期待的减肥药orforglipron进行了快速审查。","market":"us","thumbnail":"https://community-static.tradeup.com/news/b709e81a1b4f7405bf5e343b3c9425a7","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/b709e81a1b4f7405bf5e343b3c9425a7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"aad815d0c6beee6ce1e194810f0ba331","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALB","BIIB","IFF","ABBV","VRTX","BDX","DVN","MRK","LLY","CSCO"],"gpt_icon":1},{"id":"1180995314","title":"异动解读 | 渤健公司下调全年利润预期，盘前股价大跌5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180995314","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180995314?lang=zh_cn&edition=full","pubTime":"2025-10-30 21:30","pubTimestamp":1761831039,"startTime":"0","endTime":"0","summary":"周四盘前交易中，渤健公司股价大幅下跌5.65%，引发市场关注。消息面上，渤健公司下调了2025年的全年利润预期。公司表示，预计第四季度某些与收购相关的研发支出将导致每股利润下降1.25美元。渤健公司将2025年调整后每股利润预期从此前的15.50美元至16.00美元区间，下调至14.50美元至15.00美元之间。尽管渤健公司第三季度业绩表现亮眼，每股收益达4.81美元，远超分析师平均预期的3.88美元，但下调全年利润预期的消息仍然对股价造成了显著影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BIIB"],"gpt_icon":0},{"id":"1175389152","title":"渤健公司将在2025年ACR大会上发布Dapirolizumab Pegol在系统性红斑狼疮的第三阶段研究的额外结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1175389152","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175389152?lang=zh_cn&edition=full","pubTime":"2025-10-22 19:31","pubTimestamp":1761132677,"startTime":"0","endTime":"0","summary":"渤健公司将在2025年ACR大会上发布Dapirolizumab Pegol在系统性红斑狼疮的第三阶段研究的额外结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","BK4532","BK4533","IE00B894F039.SGD","BIIB","BK4588","BK4139","LU0889565916.HKD","LU0320765992.SGD","LU0234570918.USD","LU0109394709.USD","BK4585","IE00B19Z9P08.USD"],"gpt_icon":0},{"id":"1196006875","title":"渤健公司(Biogen)预计第三季度业绩将包含约200万美元税前收购研发及里程碑费用","url":"https://stock-news.laohu8.com/highlight/detail?id=1196006875","media":"美股速递","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196006875?lang=zh_cn&edition=full","pubTime":"2025-10-15 04:23","pubTimestamp":1760473399,"startTime":"0","endTime":"0","summary":"渤健公司(Biogen)预计第三季度业绩将包含收购的在研研发项目、预付款及里程碑费用，税前支出约200万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4585","BK4532","IE00B19Z9P08.USD","LU0109394709.USD","LU0234570918.USD","IE00B19Z9Z06.USD","LU0889565916.HKD","BIIB","BK4139","IE00B894F039.SGD","BK4588","BK4533"],"gpt_icon":0},{"id":"1143525294","title":"渤健公司(Biogen)预计费用支出将影响第三季度GAAP和非GAAP稀释每股净收入0.01美元——SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1143525294","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143525294?lang=zh_cn&edition=full","pubTime":"2025-10-15 04:22","pubTimestamp":1760473337,"startTime":"0","endTime":"0","summary":"渤健公司(Biogen)预计费用支出将影响第三季度GAAP和非GAAP稀释每股净收入0.01美元——SEC文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","LU0320765992.SGD","BK4139","BIIB","IE00B19Z9P08.USD","IE00B894F039.SGD","LU0234570918.USD","BK4532","LU0889565916.HKD","BK4588","LU0109394709.USD","BK4533","BK4585"],"gpt_icon":0},{"id":"2573396653","title":"渤健与卫材推出阿尔茨海默病药物的皮下注射剂型","url":"https://stock-news.laohu8.com/highlight/detail?id=2573396653","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2573396653?lang=zh_cn&edition=full","pubTime":"2025-10-07 22:47","pubTimestamp":1759848420,"startTime":"0","endTime":"0","summary":"美股周二早盘，渤健（BIIB）下跌0.8%，该公司和卫材（OTCPK：ESALF）推出阿尔茨海默病药物Leqembi的皮下注射剂型Leqembi IQLIK。该维持剂量在完成18个月输液治疗后使用，并包含患者支持计划。FDA于八月批准该新剂型。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-10-07/doc-inftavhe4145881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BIIB","LU0109394709.USD","BK4585","LU0234570918.USD","IE00B19Z9P08.USD","IE00B894F039.SGD","LU0320765992.SGD","BK4532","IE00B19Z9Z06.USD","BK4139","LU0889565916.HKD","BK4533"],"gpt_icon":0},{"id":"1166802852","title":"Eisai与渤健公司宣布Leqembi® Iqlik™皮下注射维持剂量在美国上市，用于治疗早期阿尔茨海默病","url":"https://stock-news.laohu8.com/highlight/detail?id=1166802852","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166802852?lang=zh_cn&edition=full","pubTime":"2025-10-07 04:31","pubTimestamp":1759782679,"startTime":"0","endTime":"0","summary":"Eisai与渤健公司联合宣布，用于治疗早期阿尔茨海默病的Leqembi® Iqlik™（Lecanemab-Irmb）皮下注射维持剂量已在美国正式上市。\n这一治疗方案为早期阿尔茨海默病患者提供了新的治疗选择，通过皮下注射的方式进行维持治疗，有望为患者带来更便利的用药体验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0889565916.HKD","IE00B19Z9Z06.USD","BK4533","BK4139","BK4585","IE00B19Z9P08.USD","LU0234570918.USD","LU0109394709.USD","LU0320765992.SGD","BK4532","IE00B894F039.SGD","BIIB"],"gpt_icon":0},{"id":"1121317357","title":"一周美股牛榜 | 西部数据上周飙23%；Coinbase、Fair Isaac大涨21%；美光上涨19%；渤健、Moderna涨超 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121317357","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121317357?lang=zh_cn&edition=full","pubTime":"2025-10-06 14:13","pubTimestamp":1759731238,"startTime":"0","endTime":"0","summary":"希捷的目标价中位数为 175 美元，即便从 128 美元上调，仍暗示有 32% 的下跌空间。FICO 分数由 Fair Isaac 创建，是美国使用最广泛的信用评分体系，近 90% 的贷款机构依赖它来评估借款人的信用状况。Fair Isaac 表示，直接为贷款方和抵押贷款经销商提供 FICO 分数的渠道将提升竞争并带来价格透明度。Coinbase 在近期推文中披露了这一进展，并称这是拓展业务能力及获得更大监管覆盖的重要一步。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/9a10a25294f4ba0fbf81279b191da259","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/9a10a25294f4ba0fbf81279b191da259"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5e560b6a2a221b3e34012fdfe79997b5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FICO","WDC","BIIB","MRNA","MU","COIN"],"gpt_icon":1},{"id":"1144549168","title":"\"Leqembi®\"（Lecanemab）静脉维持给药治疗早期阿尔茨海默病在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1144549168","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144549168?lang=zh_cn&edition=full","pubTime":"2025-09-29 07:34","pubTimestamp":1759102453,"startTime":"0","endTime":"0","summary":"\"Leqembi®\"（Lecanemab）静脉维持给药用于治疗早期阿尔茨海默病已在中国获得批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","BK4532","BK4533","IE00B894F039.SGD","BIIB","BK4588","BK4139","LU0889565916.HKD","LU0320765992.SGD","LU0234570918.USD","LU0109394709.USD","BK4585","IE00B19Z9P08.USD"],"gpt_icon":0},{"id":"2568408064","title":"百健(BIIB.US)拟收购Alcyone 拓展药物递送解决方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2568408064","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568408064?lang=zh_cn&edition=full","pubTime":"2025-09-18 21:40","pubTimestamp":1758202810,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百健周四宣布，同意收购总部位于马萨诸塞州的Alcyone Therapeutics，此举将拓展其关键产品及管线候选药物的药物递送解决方案组合。该交易包括一笔8500万美元的预付款，以及与ThecaFlex DRx的开发和监管批准相关的额外里程碑付款。这笔交易使百健获得ThecaFlex DRx的全部权利。ThecaFlex DRx有望为神经系统疾病患者提供一种全新的便捷给药方式。交易完成后，加入百健的Alcyone员工将被整合到产品交付解决方案团队，增强百健在药物-设备组合产品方面的能力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1346995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百健(BIIB.US)拟收购Alcyone 拓展药物递送解决方案","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B19Z9Z06.USD","BK4532","BK4533","IE00B894F039.SGD","BIIB","BK4588","BK4139","LU0889565916.HKD","LU0320765992.SGD","LU0234570918.USD","LU0109394709.USD","BK4585","IE00B19Z9P08.USD"],"gpt_icon":0},{"id":"1123195233","title":"渤健公司将收购Alcyone Therapeutics，为核心产品和管线候选药物扩展药物递送解决方案组合","url":"https://stock-news.laohu8.com/highlight/detail?id=1123195233","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123195233?lang=zh_cn&edition=full","pubTime":"2025-09-18 19:41","pubTimestamp":1758195688,"startTime":"0","endTime":"0","summary":"渤健公司将收购Alcyone Therapeutics，为核心产品和管线候选药物扩展药物递送解决方案组合","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","LU0109394709.USD","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","LU0234570918.USD","LU0320765992.SGD","IE00B894F039.SGD","LU0889565916.HKD","BK4588","IONS","BK4139","BK4532","BK4585","BK4533"],"gpt_icon":0},{"id":"1163100281","title":"Eisai向美国FDA提交Leqembi® Iqlik™皮下注射起始剂量的生物制品许可补充申请，用于治疗早期阿尔茨海默病并获快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1163100281","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163100281?lang=zh_cn&edition=full","pubTime":"2025-09-03 07:31","pubTimestamp":1756855879,"startTime":"0","endTime":"0","summary":"Eisai公司已启动向美国食品药品监督管理局(FDA)提交Leqembi® Iqlik™ (Lecanemab-Irmb)的滚动式生物制品许可补充申请，该申请涉及皮下注射起始剂量用于治疗早期阿尔茨海默病，并已获得快速通道资格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4139","BK4533","BIIB","BK4585","IE00B894F039.SGD","IE00B19Z9P08.USD","BK4588","IE00B19Z9Z06.USD","LU0234570918.USD"],"gpt_icon":0},{"id":"2563207242","title":"渤健（BIIB）和日本卫材用于治疗阿尔茨海默症的家庭版疗法获得美国食品药品管理局（FDA）批准。Leqembi Iqli","url":"https://stock-news.laohu8.com/highlight/detail?id=2563207242","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563207242?lang=zh_cn&edition=full","pubTime":"2025-08-30 05:19","pubTimestamp":1756502346,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","IE00B894F039.SGD","LU0234570918.USD","BK4588","LU0889565916.HKD","IE00B19Z9Z06.USD","LU0320765992.SGD","BK4585","BK4532","IE00B19Z9P08.USD","BIIB","BK4533","LU0109394709.USD"],"gpt_icon":0},{"id":"1158039342","title":"FDA批准Leqembi® Iqlik™（Lecanemab-Irmb）皮下注射剂用于早期阿尔茨海默病的维持治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1158039342","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158039342?lang=zh_cn&edition=full","pubTime":"2025-08-30 05:00","pubTimestamp":1756501225,"startTime":"0","endTime":"0","summary":"FDA批准Leqembi® Iqlik™（Lecanemab-Irmb）皮下注射剂用于早期阿尔茨海默病的维持治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0320765992.SGD","BK4588","IE00B19Z9P08.USD","LU0109394709.USD","LU0889565916.HKD","IE00B19Z9Z06.USD","LU0234570918.USD","BK4585","BK4139","BIIB","IE00B894F039.SGD","BK4533"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biogen.com","stockEarnings":[{"period":"1week","weight":-0.0065},{"period":"1month","weight":0.1935},{"period":"3month","weight":0.2916},{"period":"6month","weight":0.3577},{"period":"1year","weight":0.1237},{"period":"ytd","weight":0.182}],"compareEarnings":[{"period":"1week","weight":0.0062},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0536},{"period":"6month","weight":0.1415},{"period":"1year","weight":0.1324},{"period":"ytd","weight":0.1669}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性的生物制药公司，专注于为患有严重神经和神经退行性疾病的患者以及相关的治疗邻接患者发现、开发和提供全球创新疗法。该公司的核心增长领域包括多发性硬化症（MS）和神经免疫学；阿尔茨海默病（AD）和痴呆症；神经肌肉疾病，包括脊髓肌萎缩症（SMA）和肌萎缩侧索硬化症（ALS）；运动障碍，包括帕金森氏症；以及眼科学。该公司还专注于在免疫学、神经认知障碍、急性神经学和疼痛等新兴增长领域发现、开发和提供全球创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.558824,"avgChangeRate":0.039728},{"month":2,"riseRate":0.411765,"avgChangeRate":-0.004843},{"month":3,"riseRate":0.5,"avgChangeRate":-0.023281},{"month":4,"riseRate":0.323529,"avgChangeRate":-0.021192},{"month":5,"riseRate":0.617647,"avgChangeRate":0.03339},{"month":6,"riseRate":0.470588,"avgChangeRate":0.016596},{"month":7,"riseRate":0.676471,"avgChangeRate":0.034715},{"month":8,"riseRate":0.588235,"avgChangeRate":0.030673},{"month":9,"riseRate":0.5,"avgChangeRate":0.023197},{"month":10,"riseRate":0.542857,"avgChangeRate":0.058896},{"month":11,"riseRate":0.6,"avgChangeRate":0.018187},{"month":12,"riseRate":0.457143,"avgChangeRate":0.034932}],"exchange":"NASDAQ","name":"渤健公司","nameEN":"Biogen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"渤健公司,BIIB,渤健公司股票,渤健公司股票老虎,渤健公司股票老虎国际,渤健公司行情,渤健公司股票行情,渤健公司股价,渤健公司股市,渤健公司股票价格,渤健公司股票交易,渤健公司股票购买,渤健公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}